Cytopenias are common in the adult population, with increasing recognition of clonal hematopoiesis and inherited syndromes due to widespread molecular testing. Clonal hematopoiesis is a premalignant spectrum of disorders characterized by a somatic myeloid mutation, including clonal hematopoiesis of indeterminate potential and clonal cytopenia of uncertain significance. Inherited bone marrow failure syndromes (IBMFS) can also be found during workup of incidental cytopenias, even in the absence of other syndromic associations. In clonal cytopenia of uncertain significance, the overall risk of progressing to a myeloid neoplasm can be affected by the type of mutation, number of mutations, and variant allele frequency. Prognostication systems, such as the Clonal Hematopoiesis Risk Score, MN-predict, and Clonal Cytopenia Risk Score, can help determine the risk of malignant progression. Context-dependent factors like chemotherapy, radiation, and smoking can influence this risk. For suspected IBFMS, workup typically includes telomere length testing and chromosomal breakage analysis, along with comprehensive germline testing. If IBMFS is confirmed, further testing may be indicated based on the syndrome, as patients are often at risk of other organ dysfunction and malignancies. In these patients, stem cell transplantation may be indicated.

1.
van Zeventer
IA
,
de Graaf
AO
,
van der Klauw
MM
, et al
.
Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality
.
Blood Adv
.
2021
;
5
(
17
):
3266
-
3278
.
2.
Valent
P
,
Orazi
A
,
Steensma
DP
, et al
.
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
.
Oncotarget
.
2017
;
8
(
43
):
73483
-
73500
.
3.
Jaiswal
S
,
Fontanillas
P
,
Flannick
J
, et al
.
Age-related clonal hematopoiesis associated with adverse outcomes
.
N Engl J Med
.
2014
;
371
(
26
):
2488
-
2498
.
4.
Weeks
LD
,
Ebert
BL
.
Causes and consequences of clonal hematopoiesis
.
Blood
.
2023
;
142
(
26
):
2235
-
2246
.
5.
Young
AL
,
Challen
GA
,
Birmann
BM
,
Druley
TE
.
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
.
Nat Commun
.
2016
;
7
:
12484
.
6.
Steensma
DP
,
Bejar
R
,
Jaiswal
S
, et al
.
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
.
Blood
.
2015
;
126
(
1
):
9
-
16
.
7.
Malcovati
L
,
Gallì
A
,
Travaglino
E
, et al
.
Clinical significance of somatic mutation in unexplained blood cytopenia
.
Blood
.
2017
;
129
(
25
):
3371
-
3378
.
8.
Gaulin
C
,
Kelemen
K
,
Arana Yi
C
.
Molecular pathways in clonal hematopoiesis: from the acquisition of somatic mutations to transformation into hematologic neoplasm
.
Life (Basel)
.
2022
;
12
(
8
):
1135
.
9.
Niroula
A
,
Sekar
A
,
Murakami
MA
, et al
.
Distinction of lymphoid and myeloid clonal hematopoiesis
.
Nat Med
.
2021
;
27
(
11
):
1921
-
1927
.
10.
Galli
A
,
Todisco
G
,
Catamo
E
, et al
.
Relationship between clone metrics and clinical outcome in clonal cytopenia
.
Blood
.
2021
;
138
(
11
):
965
-
976
.
11.
Weeks
LD
,
Niroula
A
,
Neuberg
D
, et al
.
Prediction of risk for myeloid malignancy in clonal hematopoiesis
.
NEJM Evid
.
2023
;
2
(
5
):10.1056/evidoa2200310.
12.
Khoury
JD
,
Solary
E
,
Abla
O
, et al
.
The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/ dendritic neoplasms
.
Leukemia
.
2022
;
36
(
7
):
1703
-
1719
.
13.
Arber
DA
,
Orazi
A
,
Hasserjian
RP
, et al
.
International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data
.
Blood
.
2022
;
140
(
11
):
1200
-
1228
.
14.
Li
M
,
Baranwal
A
,
Chen
D
, et al
.
Outcome of TP53-mutated CCUS and the risk of progression to myeloid neoplasms
.
JCO
.
2023
;
41
(
16
):
7059
.
15.
Abelson
S
,
Collord
G
,
Ng
SWK
, et al
.
Prediction of acute myeloid leukaemia risk in healthy individuals
.
Nature
.
2018
;
559
(
7714
):
400
-
404
.
16.
Gu
M
,
Kovilakam
SC
,
Dunn
WG
, et al
.
Multiparameter prediction of myeloid neoplasia risk
.
Nat Genet
.
2023
;
55
(
9
):
1523
-
1530
.
17.
Xie
Z
,
Komrokji
R
,
Al Ali
N
, et al
.
Risk prediction for clonal cytopenia: multicenter real-world evidence
.
Blood
.
2024
;
144
(
19
):
2033
-
2044
.
18.
Bick
AG
,
Weinstock
JS
,
Nandakumar
SK
, et al
.
Inherited causes of clonal haematopoiesis in 97,691 whole genomes
.
Nature
.
2020
;
586
(
7831
):
763
-
768
.
19.
Bolton
KL
,
Ptashkin
RN
,
Gao
T
, et al
.
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
.
Nat Genet
.
2020
;
52
(
11
):
1219
-
1226
.
20.
Eskelund
CW
,
Husby
S
,
Favero
F
, et al
.
Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL
.
Blood
.
2020
;
135
(
22
):
2000
-
2004
.
21.
Nead
KT
,
Kim
T
,
Joo
L
, et al
.
Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomes
.
Blood Adv
.
2024
;
8
(
19
):
5215
-
5224
.
22.
Arends
CM
,
Kopp
K
,
Hablesreiter
R
, et al
.
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer
.
Leukemia
.
2024
;
38
(
6
):
1378
-
1389
.
23.
Baeten
JT
,
Chan
ICC
,
Moukarzel
L
, et al
.
Impact of PARP inhibitor and platinum therapy on clonal hematopoiesis
.
Blood
.
2023
;
142
(suppl
1
):
1315
.
24.
Sperling
AS
,
Guerra
VA
,
Kennedy
JA
, et al
.
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
.
Blood
.
2022
;
140
(
16
):
1753
-
1763
.
25.
Chien
KS
,
Ong
F
,
Kim
K
, et al
.
Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms
.
Cancer Med
.
2024
;
13
(
5
):
e7093
.
26.
Dawoud
AAZ
,
Tapper
WJ
,
Cross
NCP
.
Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking
.
Leukemia
.
2020
;
34
(
10
):
2660
-
2672
.
27.
Li
MM
,
Chao
E
,
Esplin
ED
, et al
.
Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG)
.
Genet Med
.
2020
;
22
(
7
):
1142
-
1148
.
28.
The University of Chicago Hematopoietic Malignancies Cancer Risk Team
.
How I diagnose and manage individuals at risk for inherited myeloid malignancies
.
Blood
.
2016
;
128
(
14
):
1800
-
1813
.
29.
Feurstein
S
,
Trottier
AM
,
Estrada-Merly
N
, et al
.
Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages
.
Blood
.
2022
;
140
(
24
):
2533
-
2548
.
30.
Tsai
FD
,
Lindsley
RC
.
Clonal hematopoiesis in the inherited bone marrow failure syndromes
.
Blood
.
2020
;
136
(
14
):
1615
-
1622
.
31.
Cunningham
L
,
Merguerian
M
,
Calvo
KR
, et al
.
Natural history study of patients with familial platelet disorder with associated myeloid malignancy
.
Blood
.
2023
;
142
(
25
):
2146
-
2158
.
32.
Kusne
Y
,
Badar
T
,
Lasho
T
, et al
.
Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome
.
Br J Haematol
.
2025
;
206
(
4
):
1109
-
1120
.
33.
Liu
J
,
Osman
AEG
,
Bolton
K
,
Godley
LA
.
Germline predisposition to clonal hematopoiesis
.
Leuk Res
.
2023
;
132
:
107344
.
34.
Martin
ES
,
Ferrer
A
,
Mangaonkar
AA
, et al
.
Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes
.
Am J Hematol
.
2021
;
96
(
11
):
1450
-
1460
.
35.
Xie
Z
,
Komrokji
Z
,
Otterstatter
M
, et al
.
High-risk CCUS is clinically indistinguishable from low-risk myelodysplastic syndromes/neoplasms
.
Blood
.
2024
;
144
(suppl
1
):
354
.
36.
Li
M
,
Binder
M
,
Lasho
T
, et al
.
Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients
.
Blood Adv
.
2021
;
5
(
8
):
2272
-
2278
.
37.
Taborda
CC
,
Zeidan
AM
,
Mendez
LM
.
Clonal cytopenia of undetermined significance: definitions, risk and therapeutic targets
.
Front Hematol
.
2024
;
3
:
1419323
.
38.
Petrone
G
,
Stein
EM
,
Bolton
KL
.
Ivosidenib for patients with clonal cytopenia of undetermined significance and mutations in IDH1
.
Blood
.
2023
;
142
(suppl
1
):
3253
.
39.
Borate
UM
,
Dvorak-Kornaus
KM
,
Zhao
Q
,
Eisfeld
A
,
Mundy-Bosse
BL
.
A randomized double-blind placebo-controlled phase II multi-center study of inflammation modification of canakinumab to prevent leukemic progression of clonal cytopenias of unknown significance (CCUS): impact study
.
Blood
.
2023
;
142
(suppl
1
):
1327
.
40.
Jaiswal
S
,
Natarajan
P
,
Silver
AJ
, et al
.
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
.
N Engl J Med
.
2017
;
377
(
2
):
111
-
121
.
You do not currently have access to this content.